test tube close up

Abliva

Stockholm: ABLI

Market CapSEK230m

Last Close SEK0.57

Abliva is a Swedish biotech with deep expertise in mitochondrial medicine. Its lead assets are KL1333, an NAD+ modulator (Phase II/III ready) and NV354, a succinate prodrug (preclinical). Abliva plans to start a pivotal Phase II/III trial with KL1333 in selected PMDs later this year.

More Abliva content >

Investment summary

Abliva is focused on primary mitochondrial diseases (PMD). The core portfolio consists of KL1333 and NV354. KL1333, a small molecule NAD+ modulator used to restore intracellular energy balance, is being developed for PMD, including patients with m.3243 A>G mutations (eg MELAS-MIDD spectrum disorders). Abliva completed a Phase Ia/b study and a drug-drug interaction study for KL1333 in March 2021 and it intends to start a single pivotal Phase II/III efficacy study in H221. In March, Abliva also completed a directed share issue raising SEK80m gross proceeds, c SEK64m of which will be used for KL1333. Abliva intends to continue developing its other core asset NV354 as a systemic treatment for Leigh syndrome and is expecting to prepare a clinical trial application in 2021.

Y/E Dec
Revenue (SEKm)
EBITDA (SEKm)
PBT (SEKm)
EPS (fd) (öre)
P/E (x)
P/CF (x)
2019A 3.6 (72.3) (74.6) (43.50) N/A N/A
2020A 1.9 (55.0) (57.4) (23.00) N/A N/A
2021E 1.9 (70.2) (72.7) (20.81) N/A N/A
2022E 1.9 (95.0) (97.5) (24.21) N/A N/A
Industry outlook

Abliva has a diversified portfolio, with all assets aimed at improving mitochondrial metabolism and function. We believe this puts Abliva among the very few experts in mitochondrial medicine.

Last updated on 21/09/2021
Content on Abliva
Abliva – New strategic investor on board and CMD
Healthcare | Update | 26 June 2020
science-1336663
View more
Register to receive research on Abliva as it is published
Share price graph
Balance sheet
Forecast net cash (SEKm) 66.3
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual (13.8) (15.8) (42.4)
Relative* (9.6) (18.5) (57.1)
52-week high/low SEK1.0/SEK0.6
*% relative to local index
Key management
David Laskow-Pooley Chairman
Ellen Donnelly CEO
Catharina Jz Johansson CFO
Eskil Elmér Chief Scientist Officer
Magnus Hansson Chief Medical Officer